Back

Introduction: cardiovascular disease in type 2 diabetes – Where do we come from.

26 August 2017 (15:30 - 15:40)
Organised by:
Congress Presentation Part of: Improving cardiovascular outcomes in type 2 diabetes: a novel role for GLP-1 receptor agonists? Diabetes, dysglycaemia and metabolic syndrome Open Access ESC Congress 2017

About the speaker

Photo
Professor Lars Ryden

Karolinska Institute, Stockholm (Sweden)

4 More presentations in this session

Presentation thumbnail
Cardiovascular effects of GLP-1 receptor agonists.
Doctor J. Plutzky (Boston, US)
Slides Video
Presentation thumbnail
Results from the LEADER cardiovascular outcomes trial.
Professor N. Poulter (London, GB)
Slides Video
Presentation thumbnail
Perspectives on results from recent CVOTs in type 2 diabetes.
Professor L. Ryden (Stockholm, SE)
Slides Video
Presentation thumbnail
Panel discussion - Improving CV outcomes in type 2 diabetes: A novel role for GLP-1 receptor agonists?
Professor L. Ryden (Stockholm, SE) Professor N. Poulter (London, GB) Doctor J. Plutzky (Boston, US)
Slides Video

Access the full session

Session thumbnail
Improving cardiovascular outcomes in type 2 diabetes: a novel role for GLP-1 receptor agonists?

The Event

Event poster

ESC Congress 2017

26 August 2017 15:30 CET
You may be interested in
thumbnail
Webinar
EAPC Webinar: Type 2 Diabetes and cardiovascular risk
12 March 2019
thumbnail
Congress Presentation
To improve the quality of secondary prevention strategies in diabetic patients: the BRING-UP Prevention study results
5 April 2025
thumbnail
Congress Session
Incretin-based therapies in cardiovascular practice: understanding the cardiometabolic risk continuum
31 August 2026
thumbnail
Congress Session
Diabetes, obesity, and heart failure
19 May 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources